| Detected | Trial | Change |
|---|---|---|
| 2026-08-14 | NCT05001880 Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma · National Cancer Institute (NCI) |
date change Primary completion pushed: 2026-08-20 -> 2027-08-01 |
| 2026-08-14 | NCT05001880 Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma · National Cancer Institute (NCI) |
date change Completion pushed: 2026-08-20 -> 2027-08-01 |
| 2026-08-12 | NCT07234058 Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus… · Intergroupe Francophone de Cancerologie Thoracique |
Recruitment opened |
| 2026-08-12 | NCT00715611 Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation… · Memorial Sloan Kettering Cancer Center |
date change Primary completion pushed: 2026-07 -> 2027-07 |
| 2026-08-12 | NCT00715611 Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation… · Memorial Sloan Kettering Cancer Center |
date change Completion pushed: 2026-07 -> 2027-07 |
| 2026-08-11 | NCT06840834 Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose… · Intergroupe Francophone de Cancerologie Thoracique |
date change Primary completion pushed: 2026-03-24 -> 2026-09-30 |
| 2026-08-09 | NCT06031636 Oncolytic Adenovirus(H101) Combined With PD-1 Inhibitors in Patients With Advanced… · Tianjin Medical University Second Hospital |
overall status: Recruiting → Unknown |
| 2026-08-09 | NCT05930665 Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line… · Sun Yat-sen University |
overall status: Recruiting → Unknown |
| 2026-08-05 | NCT07192900 Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease · David Bartlett, MD |
date change Primary completion pushed: 2032-12 -> 2033-04 |
| 2026-08-05 | NCT07192900 Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease · David Bartlett, MD |
date change Completion pushed: 2037-12 -> 2038-04 |
| 2026-08-02 | NCT06491784 EXTRA-Meso (EXercise TheRApy in Mesothelioma) Feasibility · NHS Greater Glasgow and Clyde |
overall status: Recruiting → Unknown |
| 2026-08-01 | NCT05703854 Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction… · M.D. Anderson Cancer Center |
critical Recruitment suspended |
| 2026-08-01 | NCT05703854 Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction… · M.D. Anderson Cancer Center |
critical Recruitment suspended: PI Request |
| 2026-08-01 | NCT00242723 Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung… · National Cancer Institute (NCI) |
Primary endpoint(s) modified |
| 2026-07-28 | NCT01843374 Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With… · MedImmune LLC |
date change Completion pushed: 2026-06-30 -> 2027-05-31 |
| 2026-07-28 | NCT03830229 Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations… · National Cancer Institute (NCI) |
date change Primary completion pushed: 2026-07-06 -> 2032-12-31 |
| 2026-07-28 | NCT03830229 Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations… · National Cancer Institute (NCI) |
date change Completion pushed: 2027-07-05 -> 2034-12-31 |
| First Posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-07-20 | NCT07713732 TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors | Treeline Biosciences, Inc. NEW | Phase 1 |
| 2026-07-15 | NCT07705334 A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic… | SHY Therapeutics NEW | Phase 1 |
| 2026-07-15 | NCT07705074 FAPI PET Imaging - An Exploratory Study | Martin Huellner NEW | Phase 1/2 |
| 2026-05-22 | NCT07602946 SELECTmeso A Trial for Patients With Relapsed Malignant Mesothelioma SELECTmeso1 A Trial… | University of Southampton NEW | Phase 2 |
| NCT ID | Title | Sponsor | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT04996017 | Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma… | Gruppo Oncologico Italiano di Ricerca Clinica | Recruiting |
| NCT06097728 | MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural… | AstraZeneca | Active, Not Recruiting |
| Phase 2 | |||
| NCT06543069 | Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting |
| NCT06875076 | Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in… | The First Hospital of Jilin University | Recruiting |
| NCT04515836 | Olaparib in Patients With HRD Malignant Mesothelioma | University of Chicago | Recruiting |
| NCT05188859 | First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in… | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting |
| NCT06790082 | The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma | Aalborg University Hospital | Recruiting |
| NCT04400539 | The IMmunotherapy Pleural 5-ALA PDT | University Hospital, Lille | Recruiting |
| NCT05730816 | MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI | Brigham and Women's Hospital | Recruiting |
| NCT06638931 | Agnostic Therapy in Rare Solid Tumors | Instituto do Cancer do Estado de São Paulo | Recruiting |
| NCT03007030 | Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be… | M.D. Anderson Cancer Center | Recruiting |
| NCT06503146 | 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer… | National Cancer Institute (NCI) | Recruiting |
| NCT06477419 | A Study of Sacituzumab Govitecan in People With Mesothelioma | Memorial Sloan Kettering Cancer Center | Recruiting |
| NCT06535607 | Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in… | AstraZeneca | Recruiting |
| NCT06057935 | A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal… | Memorial Sloan Kettering Cancer Center | Recruiting |
| NCT05647265 | Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid… | Alliance for Clinical Trials in Oncology | Recruiting |
| NCT06840834 | Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose… | Intergroupe Francophone de Cancerologie Thoracique | Recruiting |
| NCT07234058 | Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus… | Intergroupe Francophone de Cancerologie Thoracique | Recruiting |
| NCT05001880 | Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma | National Cancer Institute (NCI) | Recruiting |
| NCT04300244 | Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With… | Åslaug Helland | Active, Not Recruiting |
| NCT05425576 | OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma… | Oncotelic Inc. | Not Yet Recruiting |
| NCT06416930 | Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural… | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not Yet Recruiting |
| NCT04287829 | Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural… | The Netherlands Cancer Institute | Active, Not Recruiting |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with… | SOLTI Breast Cancer Research Group | Active, Not Recruiting |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors… | Merck Sharp & Dohme LLC | Active, Not Recruiting |